Bcl-2在嗅神经母细胞瘤中的表达及其与化疗和生存的关系。

Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival.

作者信息

Kim Jeong-Whun, Kong Il Gyu, Lee Chul Hee, Kim Dong Young, Rhee Chae-Seo, Min Yang-Gi, Kim Chul Woo, Chung Jin-Haeng

机构信息

Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

出版信息

Otolaryngol Head Neck Surg. 2008 Nov;139(5):708-12. doi: 10.1016/j.otohns.2008.03.011.

DOI:10.1016/j.otohns.2008.03.011

PMID:18984268

Abstract

OBJECTIVE

This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB).

STUDY DESIGN AND SETTING

Seventeen patients with ONB (23 tumor specimens) were included. Each specimen was studied for bcl-2, p53, MIC-2 by immunohistochemistry and for N-myc by chromogenic in situ hybridization.

RESULTS

Twelve (70%) of 17 patients and 15 (65%) of 23 specimens showed positive reactivity for bcl-2. Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission. Another patient without bcl-2 expression had no response to chemotherapy. Five patients who showed partial positivity achieved partial remission. Survival and bcl-2 expression tended to correlate, but it was not statistically significant (P = 0.06). All of the ONB specimens were negative for N-myc. Positive immunoreactivity for MIC-2 or p53 was found only in one specimen.

CONCLUSION

Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy. In addition, Bcl-2 expression tended to be associated with worse survival.

摘要

目的

本研究旨在确定肿瘤标志物在嗅神经母细胞瘤（ONB）中的预后价值。

研究设计与设置

纳入17例ONB患者（23个肿瘤标本）。通过免疫组织化学对每个标本进行bcl-2、p53、MIC-2检测，通过显色原位杂交进行N-myc检测。

结果

17例患者中有12例（70%）、23个标本中有15个（65%）bcl-2呈阳性反应。在接受新辅助化疗的7例患者中，1例bcl-2弥漫性表达的患者达到完全缓解。另1例无bcl-2表达的患者对化疗无反应。5例部分阳性的患者达到部分缓解。生存与bcl-2表达有相关趋势，但无统计学意义（P = 0.06）。所有ONB标本N-myc均为阴性。仅在1个标本中发现MIC-2或p53呈阳性免疫反应。